MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company based in New York, has announced that its abstract featuring the investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the American Thoracic Society (ATS) International Conference 2026. This event is scheduled to be held from May 15-20, 2026, in Orlando, Florida. The abstract, titled "Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell (agenT-797) Combination Immunotherapy for Unresolving Coccidioides immitis Infection," highlights a novel approach to treating severe and persistent infections through immune activation. Dr. Terese Hammond will present the findings on May 20, 2026, during the session titled "Zebras of the Lung: Rare Infections, Immune Extremes, and Diagnostic Plot Twists." MiNK Therapeutics is committed to advancing its proprietary iNKT cell therapies, with agenT-797 being a key candidate designed to enhance immune responses against difficult-to-treat tumors and improve outcomes for patients with severe respiratory conditions. Full details of the study will be disclosed at the conference, in accordance with ATS guidelines.